Wild-Type ATTR Amyloidosis
New wild-type ATTR amyloidosis research, summarized each month in plain language.
2026 so far: In the months covered, routine-care cohorts strengthened the link between tafamidis use and better survival. Trial analyses also described vutrisiran's effects on daily-life measures and left atrial strain (how well the heart's left upper chamber stretches). Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Tafamidis and survival. Several routine-care analyses reported survival differences between people who did and did not receive tafamidis.
- Vutrisiran trial findings. Trial analyses went beyond overall scores and looked at specific day-to-day impacts.
- Emerging therapies. A range of new approaches were reported, but the evidence remained early and exploratory.
- Function and frailty. Studies linked outcomes not only to heart measures, but also to independence and fatigue.
- Rhythm and conduction. Monitoring studies highlighted arrhythmias, slowed conduction, and the role of devices.
New
September 2026
- Frailty and support needs. Frailty and needing help at home were linked to higher death risk.
- Heart conduction slowing. Heart electrical conduction slowed over one year during tafamidis.
- Time to diagnosis. Longer time from symptoms to diagnosis was linked to higher mortality.
August 2026
- Tafamidis survival. In routine care, tafamidis was linked to longer survival.
- Left atrial strain. This ultrasound measure tracked risk and worsened slower on vutrisiran.
- Daily burden drivers. Fatigue and function limits related to distress more than imaging.
- Switch study status. A tafamidis-to-acoramidis switch study began; results are not yet available.
July 2026
- Exercise test groups. Breathing-based exercise groups matched walking distance and symptom class.
- Number-based heart scans. Small study: scan uptake numbers fell after tafamidis.
- Real-world care examples. Case reports described monitoring choices and complex valve decisions.
June 2026
- Transplant survival. Five-year survival was similar after transplant across amyloidosis types.
- Post-transplant problems. Infections were common, and neuropathy sometimes worsened over time.
- Incomplete testing. Many people lacked full testing before ATTRwt was recorded.
- Tafamidis lab signals. Early lab work linked tafamidis to lower blood-vessel cell stress.
May 2026
- Blood TTR lowering. Vutrisiran lowered blood transthyretin (TTR) levels substantially across the ATTR groups studied.
- Baseline MRI risk signals. Higher amyloid-related measures on the first heart MRI were linked with a higher chance of later worsening.
- Rhythm findings on monitoring. Continuous rhythm monitoring found slow heart rhythms and new atrial fibrillation in amyloid heart disease.
- Gut and inflammation signals. Small early studies reported links between gut bacteria patterns, inflammation markers, and ATTR.
April 2026
- Tafamidis and survival. In routine-care data, tafamidis use was linked with lower death rates.
- Who starts tafamidis. In one large cohort, women started tafamidis less often than men.
- Heart radiotherapy (early study). In a 5-person study, low-dose heart radiotherapy was reported as tolerable over 6 months, with early PET scan changes.
- Earlier heart detection tools. New scans and ECG software sometimes detected ATTR heart involvement earlier, but these tools are not yet proven and did not perform equally well across settings.
March 2026
- Daily activity symptoms. Vutrisiran showed small, steady advantages on patient questionnaires about everyday activities.
- Heart risk grouping. Using several heart imaging measures together separated higher- and lower-risk outlook groups better than using one measure alone.
- ECG does not rule out ATTR. Low ECG voltage was often not present, so its absence did not rule out ATTR.
February 2026
- Faster confirmation. Once suspected, confirmation often did not require a heart biopsy.
- Ultrasound cutoffs. Standard echo cutoffs may miss some women without sex-specific thresholds.
- Heart event history. A past acute coronary syndrome was linked with higher risk.
- Autonomic changes. Autonomic testing found measurable changes despite few symptoms.
January 2026
- Earlier diagnosis signals. Screening and test patterns may find wtATTR earlier, not proven.
- Risk grouping measures. Right-heart measures and scan details may better group risk.
- Procedure outcomes. Stroke-prevention procedures were feasible, but later events occurred.
Get the monthly update by email
Subscribe here to receive an email when a new monthly wild-type ATTR amyloidosis update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).